Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 43 Leukemia, Myeloid, Acute 25 Recurrence 21 Lymphoma, Large B-Cell, Diffuse 12 Sarcoma 8 Neoplasms, Plasma Cell 5 Neoplasm Metastasis 5 Lymphoma 5 Glioblastoma 5 Ovarian Neoplasms 4 Neurofibrosarcoma 4 Neoplasms 4 Melanoma 4 Lymphoma, Non-Hodgkin 4 Endometrial Neoplasms 4 Colorectal Neoplasms 4 Triple Negative Breast Neoplasms 3 Precursor Cell Lymphoblastic Leukemia-Lymphoma 3 Myelodysplastic Syndromes 3 Lymphoma, T-Cell, Peripheral 3 Lymphoma, Extranodal NK-T-Cell 3 Lymphoma, B-Cell 3 Liposarcoma 3 Glioma 3 Carcinoma, Non-Small-Cell Lung 3 Carcinoma 3 Waldenstrom Macroglobulinemia 2 Thymoma 2 Sarcoma, Alveolar Soft Part 2 Rhabdoid Tumor 2

Interventions

midostaurin 2 selinexor 1 pegfilgrastim 1 glofitamab 1 Topotecan 1 Rituximab 1 Prednisone 1 Paclitaxel 1 Methylprednisolone 1 Immunologic Techniques 1 Ifosfamide 1 Flow Cytometry 1 Etoposide 1 Dexamethasone 1 Clofarabine 1 Carboplatin 1 Bexarotene 1 Alemtuzumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Aggression × selinexor × Clear all

NCT02471911 2022-04-12

KPT-330+RICE

Weill Medical College of Cornell University

Phase 1 Completed

Aggression, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon ⚡